Clinical Trials Logo

Type 2 Diabetes clinical trials

View clinical trials related to Type 2 Diabetes.

Filter by:

NCT ID: NCT05781334 Not yet recruiting - Heart Failure Clinical Trials

Optimizing In-hospital Use of Evidence-based Therapies for Patients With Cardio-Renal-Metabolic Disease

IMPLEMENT-CRM
Start date: June 1, 2023
Phase: N/A
Study type: Interventional

This study will be a prospective randomized implementation trial for patients hospitalized with heart failure, chronic kidney disease, and/or type 2 diabetes mellitus within Duke University Medical Center. The primary hypothesis is that a virtual quality improvement-based consult intervention will improve the rate of in-hospital evidence-based cardio-renal-metabolic medication use, particularly SGLT2 inhibitor therapy. Approximately 200 patients meeting eligibility criteria will be included in the study. Patients will be assigned into study groups, as defined by randomization of their treating clinician team to receiving the virtual consult versus not.

NCT ID: NCT05774015 Not yet recruiting - Type 2 Diabetes Clinical Trials

Effect of Oral Magnesium Supplementation on Type II Diabetes Mellitus Guided by Serum Ionized Magnesium Level

Start date: September 2023
Phase: N/A
Study type: Interventional

Studies have shown that type 2 diabetic patients (T2DM) may have low serum magnesium levels leading to poor control and outcome of the disease. Supplementation with Mg might improve overall diabetic control and disease outcome. However, there is yet no consensus on whether the ionized (iMg) or the total Mg (tMg) level should be used as a basis to determine the status of Mg in the blood. Recently it was shown that iMg may correlate better with diabetes control than tMg. Therefore, Mg supplements to diabetic patients may improve their disease status. Unfortunately, and to the best of our knowledge all of the available trials on Mg supplementation guided by iMg levels were conducted on healthy volunteers rather than T2DM patients, and they were all for a short period of time (10 days to 10 weeks). Here we hypothesize that supplementations of T2DM patients with Mg based on serum iMg levels correlate better with diabetes control and prognosis. Such hypothesis is supported by a retrospective study that concluded that iMg correlate better with BP control than tMg. In addition, another trial that investigated the effects of three Mg dietary supplements; Mg oxide, Mg citrate and Mg carbonate on healthy female young adults, showed that only Mg oxide led to an increase in the levels of iMg and tMg concentrations when compared to baseline. Furthermore, a case-control study on older diabetic patients revealed a significant association between iMg and HbA1c. This study aims to investigate the effect of supplementing Mg oxide tablets versus placebo tablets guided by serum iMg levels in T2DM patients with or without hypomagnesemia on diabetic control and prognosis.

NCT ID: NCT05768958 Recruiting - Type 2 Diabetes Clinical Trials

Hedonic and Homeostatic Appetite Control in Obesity and Type 2 Diabetes in the Context of Meal and Exercise Timing

TIMEX
Start date: March 2023
Phase: N/A
Study type: Interventional

The overall aim is to investigate effects of acute exercise on ad libitum energy intake and study whether this differs between morning and evening in individuals with overweight/obesity with or without type 2 diabetes (T2D). Furthermore, the aim is to examine the role of hedonic and homeostatic drivers of appetite control in obesity and T2D in the context of meal and exercise timing.

NCT ID: NCT05766735 Not yet recruiting - Type 2 Diabetes Clinical Trials

Treating Early Type 2 Diabetes by Reducing Postprandial Glucose Excursions: A Paradigm Shift in Lifestyle Modification

GEM
Start date: March 20, 2023
Phase: N/A
Study type: Interventional

A Randomized Consent Design (RCD) trial of our hypothesis that self-administered, individualized Glycemic Excursion Minimization (GEM) treatment for adults newly diagnosed with Type 2 Diabetes (T2D), compared to individualized medication management (MM), will: 1) reduce hemoglobin A1c as much or more, 2) require less diabetes medication, 3) cost less, and 4) have more secondary benefits, (e.g. greater reduction in cardiovascular risk, weight, diabetes distress, depression symptoms).

NCT ID: NCT05766488 Not yet recruiting - Type 2 Diabetes Clinical Trials

Assessing Continuous Glucose Monitor Use in Underserved Primary Care Patients

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the perceived and experienced benefits and barriers of CGM use and identify outcomes associated with CGM use relative to usual care with self-monitoring of blood glucose in an underserved patient population with type 2 diabetes. The main questions it aims to answer are: - What are the perceived and experienced benefits of CGM use in an underserved patient population with type 2 diabetes? - What differences are there in glucose monitoring frequency and glucose control between CGM and traditional glucometer testing in an underserved patient population with type 2 diabetes? Participants will: - Complete a baseline and final survey evaluating perceived/expected benefits or barriers to CGM use - Be assigned to a CGM or usual care (traditional glucometer) arm for 6 months within an interprofessional primary care setting - Complete laboratory testing at regular intervals that don't differ from usual diabetes care Researchers will compare the CGM group to the traditional glucometer group to see if there are differences between (1) perceived/experienced benefits or barriers to the use of these devices, (2) glycemic clinical outcomes (hemoglobin A1c, hypoglycemia, hyperglycemia), and (3) glycemic measurement frequency.

NCT ID: NCT05765214 Not yet recruiting - Colorectal Cancer Clinical Trials

Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes

Start date: May 2023
Phase: N/A
Study type: Interventional

The goal of this observation study is to deliver an education program designed to increase knowledge of colorectal cancer prevention and nutrition education in minorities with Type 2 diabetes. The main questions it aims to answer are: - What factors are associated with colorectal cancer screening among patients with type 2 diabetes? - Will implementing a customized patient-centered, culturally appropriate colorectal cancer education, and nutrition education program reduce the risk for colorectal cancer among patients with type 2 diabetes? - What is the impact of a patient-centered, culturally appropriate colorectal cancer education, and nutrition education intervention program on colorectal cancer screening and dietary indices among patients with type 2 diabetes compared to outcomes with patients who do not receive the intervention (usual care)? Participants randomized to the intervention group will: - receive a customized patient-centered, culturally appropriate education program - participate in eight (8) education sessions - be given booklet with colorectal cancer education and nutrition education to use as a workbook Researchers will compare colorectal cancer knowledge, perceptions, self-care, and social norms scores and dietary indices of the intervention group to the control group immediately and 6-months post intervention to see if the education program increased colorectal cancer knowledge and screenings and changes in dietary habits.

NCT ID: NCT05762744 Terminated - Type 2 Diabetes Clinical Trials

Pharmacogenomics of GLP1 Receptor Agonists

Start date: June 1, 2016
Phase: Phase 1
Study type: Interventional

Healthy volunteers were recruited from the Old Order Amish population in Lancaster County, Pennsylvania. After providing informed consent, research participants were screened for eligibility. The clinical trial was designed as a randomized crossover study in which participants underwent two frequently sampled intravenous glucose tolerance tests - one after receiving a subcutaneous injection of saline and one after receiving a subcutaneous injection of rapid-acting exenatide (BYETTA). The study sought to determine whether genetic variants are associated with the magnitude of the effect of exenatide. If an association were identified, this would help physicians to predict whether an individual patient is likely to have a large response to the class of diabetes drugs to which exenatide belongs (GLP1 receptor agonists).

NCT ID: NCT05761886 Not yet recruiting - Type 2 Diabetes Clinical Trials

Rural Area Pharmacist Intervention for Diabetes

Start date: April 2023
Phase: N/A
Study type: Interventional

The goal of the project is to inform the system leaders regarding the feasibility and utility of having an embedded telehealth-based clinical pharmacist at rural primary care practices for supportive disease management of patients with Type 2 diabetes (T2D) and whether continuing and expanding the program within the system is worthwhile.

NCT ID: NCT05761743 Recruiting - Type 2 Diabetes Clinical Trials

Glycemic Control, Type II Diabetes, Parathyroidectomy

Start date: February 27, 2023
Phase:
Study type: Observational

The purpose of this study is to assess glycemic control after parathyroidectomy in patients with primary hyperparathyroidism and concomitant type 2 diabetes mellitus.

NCT ID: NCT05760456 Not yet recruiting - Type 2 Diabetes Clinical Trials

Safety and Efficacy of DIDALA Monotherapy in Patients With Type 2 Diabetes Compared With Metformin.

Start date: March 15, 2023
Phase: Phase 3
Study type: Interventional

This is an open-label, two-group parallel study, comparing before and after treatment within the same group and between the two groups. This study is designed to collect data on the safety and efficacy of a marketed pharmaceutical product (DIDALA) compared with Metformin. The efficacy data of DIDALA will be directly compared with Metformin 1000mg/day monotherapy in this study.